Pilot corpus only
This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.
Driven by 4 papers. Top paper: “Treatment-free survival (TFS) outcomes from the phase II study of nivolumab and salvage nivolumab + ipilimumab in advanced clear cell renal cell carcinoma (aRCC) (HCRN GU16-260-Cohort A).”.
Opeyemi A. Jegede, David F. McDermott, Naomi B. Haas, Mehmet Asım Bilen, Mark N. Stein +11 more
Opeyemi A. Jegede, Naomi B. Haas, David F. McDermott, Mehmet Asım Bilen, Mark N. Stein +11 more
Lena V. Wirth, Kelly Street, Neil Ruthen, Opeyemi A. Jegede, Nicholas R. Schindler +22 more
Miya B. Hugaboom, Kelly Street, Neil Ruthen, Opeyemi A. Jegede, Nicholas R. Schindler +22 more